Advertisement
BIO vs RVTY
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Revvity (RVTY) Stock Comparison
Key Takeaways
- Bio-Rad Laboratories (BIO) trades at a lower price-to-earnings (P/E) ratio of 9.10 compared to Revvity's (RVTY) 41.71, suggesting better relative valuation in recent market activity.
- BIO has outperformed year-to-date (YTD) with a 16.34% return versus RVTY's 11.07%, though both faced recent downward pressure.
- RVTY boasts a larger market capitalization of $9.6 billion compared to BIO's $6.8 billion, indicating greater scale.
- Recent product launches and dividend declarations have supported sentiment for RVTY, while BIO navigated challenges from first-quarter results.
- Both stocks operate in the healthcare diagnostics and life sciences sector, exposed to similar biotech spending trends and innovation drivers.
Introduction
Bio-Rad Laboratories (BIO) and Revvity (RVTY) represent key players in the life sciences and diagnostics sector, where demand for research tools, testing solutions, and health technologies drives growth. This stock comparison evaluates their recent performance, valuations, and market positioning amid evolving biotech spending and innovation cycles. Traders seeking short-term momentum and investors focused on long-term stability in healthcare will find insights into relative strengths, such as valuation multiples and growth catalysts, to inform portfolio decisions in the current market environment.
BIO Overview and Recent Performance
Bio-Rad Laboratories (BIO), headquartered in Hercules, California, develops, manufactures, and markets products for life science research and clinical diagnostics, spanning instruments, reagents, and software for protein analysis, cell separation, and disease testing. In recent weeks, BIO's stock has faced downward pressure, trading around $253 after retreating from near $280 levels, influenced by first-quarter 2026 results showing net sales of $592.1 million amid softer demand in diagnostics. Year-to-date gains stand at 16.34%, supported by a low P/E ratio of 9.10 (TTM) and strong earnings per share (EPS) of $27.84, reflecting operational efficiency despite market headwinds like biotech funding constraints. Sentiment has been tempered by analyst adjustments, including a reduced price target, yet the 52-week range of $211-$343 underscores volatility tied to quarterly execution.
RVTY Overview and Recent Performance
Revvity (RVTY), based in Waltham, Massachusetts and formerly PerkinElmer, delivers health sciences solutions including detection technologies, reagents, and software for genomics, oncology, and diagnostics. The stock has hovered around $86 in recent market activity, with year-to-date returns of 11.07% amid anticipation for upcoming earnings. Positive developments include the launch of Signals BioDesign for molecular cloning and quarterly dividend declarations, bolstering investor confidence despite a higher P/E ratio of 41.71 (TTM) and EPS of $2.06. Trading within a 52-week range of $81-$118, RVTY's performance reflects resilience in services revenue and exposure to renewed diagnostics demand, though challenged by biotech slowdowns in recent quarters.
Trending AI Robots
Tickeron's Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 351 available agents that trade thousands of tickers across diverse strategies. These bots feature impressive stats, including annualized returns ranging from 23.67% to 164.21%, win rates of 51% to 88%, and profit factors up to 11.70, with average trade durations from 1 day to 50 days. Employing styles like trend trading, swing strategies, high win-rate signals, and take-profit/stop-loss corridors, they target sectors such as semiconductors, AI infrastructure, and ETFs. Traders can explore these adaptable tools suited to current volatility for potential outperformance.
Head-to-Head Comparison
Both BIO and RVTY focus on life sciences and diagnostics, but BIO emphasizes research reagents and clinical test kits, while RVTY offers broader health tech platforms including imaging and genomic workflows. Growth drivers differ: RVTY benefits from software subscriptions and new launches like BioDesign, contrasting BIO's reliance on instrument sales amid demand softness. Recent momentum favors BIO's YTD edge, but RVTY shows stability with dividends. Risk factors include shared biotech spending cuts, though BIO's lower valuation mitigates downside versus RVTY's premium pricing. Market sentiment leans toward RVTY for scale, while BIO appeals for value in sector rotations.
Tickeron AI Verdict
Tickeron's AI models currently lean toward BIO with moderate conviction, driven by its attractive P/E multiple, superior YTD performance, and higher margins amid recent earnings scrutiny. While RVTY offers scale and catalysts like product innovation, BIO's relative undervaluation and trend stability position it favorably for potential rebound in the diagnostics space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a Hold and RVTY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 1 FA rating(s) are green whileRVTY’s FA Score has 3 green FA rating(s).
- BIO’s FA Score: 1 green, 4 red.
- RVTY’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 3 TA indicator(s) are bullish while RVTY’s TA Score has 5 bullish TA indicator(s).
- BIO’s TA Score: 3 bullish, 7 bearish.
- RVTY’s TA Score: 5 bullish, 4 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а -2.82% price change this week, while RVTY (@Medical Specialties) price change was -1.50% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.22%. For the same industry, the average monthly price growth was -3.84%, and the average quarterly price growth was -16.30%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.45%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was -3.19%.
Reported Earning Dates
BIO is expected to report earnings on Jul 30, 2026.
RVTY is expected to report earnings on Aug 03, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.22% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+0.45% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIO | RVTY | BIO / RVTY | |
| Capitalization | 7.64B | 11B | 69% |
| EBITDA | 440M | 773M | 57% |
| Gain YTD | -7.221 | 2.509 | -288% |
| P/E Ratio | 46.77 | 47.62 | 98% |
| Revenue | 2.59B | 2.9B | 89% |
| Total Cash | 1.57B | 860M | 182% |
| Total Debt | 1.38B | 3.35B | 41% |
BIO | RVTY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 83 Overvalued | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 89 | |
PRICE GROWTH RATING 1..100 | 52 | 32 | |
P/E GROWTH RATING 1..100 | 13 | 33 | |
SEASONALITY SCORE 1..100 | 90 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RVTY's Valuation (15) in the Medical Specialties industry is significantly better than the same rating for BIO (83). This means that RVTY’s stock grew significantly faster than BIO’s over the last 12 months.
RVTY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BIO (100). This means that RVTY’s stock grew similarly to BIO’s over the last 12 months.
RVTY's SMR Rating (89) in the Medical Specialties industry is in the same range as BIO (90). This means that RVTY’s stock grew similarly to BIO’s over the last 12 months.
RVTY's Price Growth Rating (32) in the Medical Specialties industry is in the same range as BIO (52). This means that RVTY’s stock grew similarly to BIO’s over the last 12 months.
BIO's P/E Growth Rating (13) in the Medical Specialties industry is in the same range as RVTY (33). This means that BIO’s stock grew similarly to RVTY’s over the last 12 months.
| BIO | RVTY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 70% | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 69% | 2 days ago 70% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 67% | 2 days ago 60% |
| Advances ODDS (%) | 8 days ago 66% | 8 days ago 65% |
| Declines ODDS (%) | 2 days ago 68% | 22 days ago 67% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 75% | 2 days ago 48% |
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.